To investigate underlying mechanisms of acquired resistance to BRAFi we induced resistance by repeatedly exposing the parental A375 BRAF V600E mutated human melanoma cell line to increasing concentrations of the BRAFi PLX4720 or the clinically used vemurafenib. This evidence concerns the gene BRAF and melanoma.